Medindia

X

Sangui Shareholders Elect Directors, Authorize Capital

Saturday, December 20, 2008 General News J E 4
Advertisement
WITTEN, Germany, December 19 The generalmeeting of shareholders of Sangui BioTech International, Inc., has resolvedupon the proposals as submitted by the board of directors. Participating were50.7% of the total of 50,000,000 shares issued and outstanding. The meetingwhich had taken place on November 18, 2008 had been adjourned to December 16,2008 in order to permit additional shareholders to submit their votes.

The Board of Directors now consists of Joachim Fleing, Hubertus Schmelzand Thomas Striepe. Over 97% of votes were cast in favor of these nominees.The amended and restated Articles of Incorporation of the company wereapproved by 71.4% of votes. The remaining proposals all obtained a majorityof above 70% and are thereby approved and ratified.

SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTechInternational, Inc. (http://www.pinksheets.com) (SGBI)

Some of the statements contained in this news release discuss futureexpectations, contain projections of results of operation or financialcondition or state other "forward-looking" information. These statements aresubject to known and unknown risks, uncertainties, and other factors thatcould cause the actual results to differ materially from those contemplatedby the statements. The forward-looking information is based on variousfactors and is derived using numerous assumptions. Important factors that maycause actual results to differ from projections include, among many others,the ability of the Company to raise sufficient capital to meet operatingrequirements. Words such as "anticipates," "expects," "intends," "plans,""believes," "seeks," "estimates," and variations of such words and similarexpressions are intended to identify such forward-looking statements. Unlessrequired by law, the Company undertakes no obligation to update publicly anyforward-looking statements, whether as a result of new information, futureevents or otherwise.For more information please contact: Joachim Fleing Phone: +49-160-741-27-17 Fax: +49-2302-915-191 e-mail: fleing@sangui.de

SOURCE Sangui Bio Tech International Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Biostar Pharmaceuticals, Inc. Commences Trading
S
Peter DeComo Appointed CEO of ALung Technologies